An interventional study of IBD Strong Peer2Peer and Waitlist control in Inflammatory Bowel Diseases, Ulcerative Colitis and Crohn Disease, sponsored by Jennifer Jones. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Jennifer Jones · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Inflammatory Bowel Diseases with a site in Canada — 35 open to participants now, 49 under way, 6 of them phase 3. Inflammatory Bowel Diseases · Canada.
Among the 155 studies in Inflammatory Bowel Diseases with a site in Canada, this one is the 60th largest by planned enrollment of the 118 interventional ones that give a count, is one of 5 that started in 2023, is one of 45 with no phase, reaches primary completion later than 18 of the 48 other live ones, and was the 121st registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →35 of the 155 studies in Inflammatory Bowel Diseases with a site in Canada are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Canada, United States, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in Canada, United States, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of British Columbia · Sites in Canada
Ages 9–17
University of British Columbia · Sites in Canada
Ages 19+ · Women only · Healthy volunteers
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 277 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 117 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 33 · Phase 3 28 · Phase 4 10
First in 2002; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 121 across the 118 interventional studies, 157 across the 36 observational. Of the 91 that completed or were terminated, 32 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 155 have an industry lead sponsor. The 10 most frequent:
Jennifer Jones is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Jennifer Jones has 2 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
15 of the studies in Inflammatory Bowel Diseases with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07814274University of British ColumbiaProspective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development | 2027-02-01 |
| NCT05722236Jennifer JonesIBD Strong Peer2Peer for Self-Management of Psychological Distress | 2027-03 |
| NCT06548399McMaster UniversityLongitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease | 2027-03-30 |
Add all 15 to your calendar (.ics) → With an account.
Among the 155 studies in Inflammatory Bowel Diseases with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Psychological distress (PD) as a result of inflammatory bowel disease (IBD) is prevalent and associated with worse disease-related outcomes. IBD-associated psychological distress (IBD-PD) is particularly common at initial diagnosis, during disease flares, before surgery, and during transitions of care. Access to evidence-based, gold-standard psychological interventions and emotional support for IBD-PD has been identified as a major care gap by persons living with IBD. The COVID-19 pandemic has further exacerbated the burden of PD for persons living with chronic diseases like IBD, predisposing at-risk individuals to even greater mental struggles. Studies have shown a minority of patients are asked about IBD-PD in routine clinical care and that even if asked, access to mental health care is extremely limited. iPeer2Peer is an evidence-based, peer-led, virtually administered intervention for IBD-PD in the pediatric population that has demonstrated feasibility, acceptability and early effectiveness. Using qualitative data derived from an extensive stakeholder engagement process, iPeer2Peer has been adapted to meet the needs of adults living with IBD-PD. This program, IBD Strong Peer, will be studied through a randomized, wait list-controlled hybrid implementation-effectiveness trial in Nova Scotia. This study will provide implementation data needed to improve and adapt the intervention and implementation strategy to meet local needs, as well as provide early effectiveness data. This data will inform the design and statistical power needed for future larger, multicenter randomized control trials. IBD Strong Peer has significant potential to improve access to evidence-informed interventions for IBD-PD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: IBD Strong Peer2Peer
Other: Waitlist control
Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
Participant Satisfaction
Satisfaction, measured by the satisfaction questionnaire: QUOTE IBD, where QI index \< 0.9 = suboptimal satisfaction)
Time frame: week 4
Participant Satisfaction
Satisfaction, measured by the satisfaction questionnaire: QUOTE IBD, where QI index \< 0.9 = suboptimal satisfaction)
Time frame: week 8
Attrition rate
Rate of participants who drop out of the study
Time frame: week 4
Attrition rate
Rate of participants who drop out of the study
Time frame: week 8
Adherence rate
Rate of participants who adhere to the study protocol
Time frame: week 4
Adherence rate
Rate of participants who adhere to the study protocol
Time frame: week 8
Recruitment success
recruitment success \[participation/ total number approached or referred\]
Time frame: Pre-study Baseline
Recruitment success
recruitment success \[participation/ total number approached or referred\]
Time frame: week 4
Recruitment success
recruitment success \[participation/ total number approached or referred\]
Time frame: week 8
Fidelity
Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).
Time frame: week 1
Fidelity
Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).
Time frame: week 2
Fidelity
Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).
Time frame: week 3
Fidelity
Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).
Time frame: week 4
Fidelity
Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).
Time frame: week 5
Fidelity
Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).
Time frame: week 6
Fidelity
Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).
Time frame: week 7
Fidelity
Audio recording of session to determine what interventions were delivered, intervention fidelity (Module content completion will be assessed via thematic analysis).
Time frame: week 8
General quality of life score (Eq5D-3L )
General quality of life score measured by the European Quality of Life 5 Dimensions 3 Level Version (Eq5D-3L) index
Time frame: Pre-study Baseline
General quality of life score (Eq5D-3L )
General quality of life score measured by the European Quality of Life 5 Dimensions 3 Level Version (Eq5D-3L) index
Time frame: week 4
General quality of life score (Eq5D-3L )
General quality of life score measured by the European Quality of Life 5 Dimensions 3 Level Version (Eq5D-3L) index
Time frame: week 8
General quality of life score (SF-36)
General quality of life score measured by the SF-36 questionnaire
Time frame: Pre-study baseline
General quality of life score (SF-36)
General quality of life score measured by the SF-36 questionnaire
Time frame: week 4
General quality of life score (SF-36)
General quality of life score measured by the SF-36 questionnaire
Time frame: week 8
IBD Related quality of life score
IBD Related quality of life score, measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Time frame: Pre-study baseline
IBD Related quality of life score
IBD Related quality of life score, measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Time frame: week 4
IBD Related quality of life score
IBD Related quality of life score, measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Time frame: week 8
Participant Self efficacy score
Self-efficacy, measured by the New General Self Efficacy Scale
Time frame: Pre-study Baseline
Participant Self efficacy score
Self-efficacy, measured by the New General Self Efficacy Scale
Time frame: week 4
Participant Self efficacy score
Self-efficacy, measured by the New General Self Efficacy Scale
Time frame: week 8
Psychological distress (DSM-V)
Participant psychological distress, measured by the DSM-V cross cutting questionnaire
Time frame: Pre-study Baseline, week 4 and week 8
Psychological distress (DSM-V)
Participant psychological distress, measured by the DSM-V cross cutting questionnaire
Time frame: week 4
Psychological distress (DSM-V)
Participant psychological distress, measured by the DSM-V cross cutting questionnaire
Time frame: week 8
Psychological distress (PSS)
Participant psychological distress, measured by the Perceived Stress Scale (PSS)
Time frame: Pre-study Baseline
Psychological distress (PSS)
Participant psychological distress, measured by the Perceived Stress Scale (PSS)
Time frame: week 4
Psychological distress (PSS)
Participant psychological distress, measured by the Perceived Stress Scale (PSS)
Time frame: week 8
Psychological distress (GAD7)
Participant psychological distress, measured by the Generalized Anxiety Disorder Assessment (GAD7) scale
Time frame: Pre-study Baseline
Psychological distress (GAD7)
Participant psychological distress, measured by the Generalized Anxiety Disorder Assessment (GAD7) scale
Time frame: week 4
Psychological distress (GAD7)
Participant psychological distress, measured by the Generalized Anxiety Disorder Assessment (GAD7) scale
Time frame: week 8
Psychological distress (PHQ8)
Participant psychological distress, measured by the eight-item Patient Health Questionnaire depression (PHQ8) scale
Time frame: Pre-study Baseline
Psychological distress (PHQ8)
Participant psychological distress, measured by the eight-item Patient Health Questionnaire depression (PHQ8) scale
Time frame: week 4
Psychological distress (PHQ8)
Participant psychological distress, measured by the eight-item Patient Health Questionnaire depression (PHQ8) scale
Time frame: week 8
Started Jun 2023 (actual). Primary completion is estimated for Mar 2027, 45 months after the start.
Of 282 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 45 months is above that.
Counting every sponsor, half of 296 studies reached it within 27 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jennifer Jones